Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/30124
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2022-12-28T06:36:46Z-
dc.date.available2022-12-28T06:36:46Z-
dc.date.issued2017-02-23-
dc.identifier.citationYılmazlar, T. vd. (2017). ''Microbiological aspects of Fournier's gangrene''. International Journal of Surgery, 40, 135-138.en_US
dc.identifier.issn1743-9191-
dc.identifier.urihttps://doi.org/10.1016/j.ijsu.2017.02.067-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1743919117301929-
dc.identifier.uri1743-9159-
dc.identifier.urihttp://hdl.handle.net/11452/30124-
dc.description.abstractBackground: Fournier's gangrene (FG) is a devastating disease that is characterized by necrotizing fasciitis of the perineal, genital, or perianal region. Broad-spectrum antibiotics are the key component of its treatment. However, there is paucity of data regarding the optimal empirical antibiotherapy for FG. Materials and methods: Data from patients who underwent surgery for FG between January 2007 and December 2012 were retrieved from a prospectively collected departmental FG database. Demographics, clinical characteristics, causative pathogens and drug susceptibility/resistance were evaluated. Results: Fifty patients with a median age of 58.5 (22-83) years were included. The perianal origin (58%) was most commonly affected. A positive growth was found in specimen cultures of 48 (96%) patients. The median number of bacterial strains that grew in the cultures was 3 (0-10). Amikacin was the antibiotic with the highest frequency of sensitivity (74%), while the highest resistance was observed against ampicillin-sulbactam (64%). Escherichia coli was the most common microorganism (72%). Acinetobacter baumannii and Klebsiella pneumonia were significantly more common in patients who required mechanical ventilation. The mortality rate was 26%. An Uludag Fournier's Gangrene Severity Index (UFGSI) score of >9.5 and ventilatory support requirement were factors associated with an increased rate of mortality. Acinetobacter baumannii was the only microorganism which was associated with an increased mortality rate. Conclusion: Causative pathogens in FG appeared to be shifting; thus, empirical antibiotic treatment for this disease should be modified. We recommend 3rd-generation cephalosporin, metronidazole and amikacin for empirical therapy.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectSurgeryen_US
dc.subjectEmpiric antimicrobial therapyen_US
dc.subjectMicrobialen_US
dc.subjectNecrotizing fasciitisen_US
dc.subjectVentilator-associated pneumoniaen_US
dc.subjectPredictorsen_US
dc.subjectManagementen_US
dc.subjectMortalityen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshAnti-bacterial agentsen_US
dc.subject.meshFemaleen_US
dc.subject.meshFournier gangreneen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMicrobial sensitivity testsen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshProspective studiesen_US
dc.titleMicrobiological aspects of Fournier's gangreneen_US
dc.typeArticleen_US
dc.identifier.wos000402486400022tr_TR
dc.identifier.scopus2-s2.0-85014506784tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Cerrahi Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-9541-5035tr_TR
dc.identifier.startpage135tr_TR
dc.identifier.endpage138tr_TR
dc.identifier.volume40tr_TR
dc.relation.journalInternational Journal of Surgeryen_US
dc.contributor.buuauthorYılmaz, Tuncay-
dc.contributor.buuauthorGülcü, Barış-
dc.contributor.buuauthorÖztürk, Ersin-
dc.contributor.buuauthorIşık, Özgen-
dc.contributor.researcheridAAW-9602-2020tr_TR
dc.contributor.researcheridP-5779-2019tr_TR
dc.contributor.researcheridABH-2238-2021tr_TR
dc.identifier.pubmed28257985tr_TR
dc.subject.wosSurgeryen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ2en_US
dc.contributor.scopusid6701800362tr_TR
dc.contributor.scopusid56618783200tr_TR
dc.contributor.scopusid36600543700tr_TR
dc.contributor.scopusid35070171400tr_TR
dc.subject.scopusFournier Gangrene; Bouteloua; Necrotizing Fasciitisen_US
dc.subject.emtreeAmikacinen_US
dc.subject.emtreeCefazolinen_US
dc.subject.emtreeCefepimeen_US
dc.subject.emtreeCephalosporinen_US
dc.subject.emtreeCiprofloxacinen_US
dc.subject.emtreeColistinen_US
dc.subject.emtreeDaptomycinen_US
dc.subject.emtreeGentamicinen_US
dc.subject.emtreeImipenemen_US
dc.subject.emtreeLevofloxacinen_US
dc.subject.emtreeMeropenemen_US
dc.subject.emtreeMetronidazoleen_US
dc.subject.emtreeMoxifloxacinen_US
dc.subject.emtreePiperacillin plus tazobactamen_US
dc.subject.emtreeSultamicillinen_US
dc.subject.emtreeTeicoplaninen_US
dc.subject.emtreeVancomycinen_US
dc.subject.emtreeAntiinfective agenten_US
dc.subject.emtreeAcinetobacter baumanniien_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeAntibiotic resistanceen_US
dc.subject.emtreeAntibiotic sensitivityen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeArtificial ventilationen_US
dc.subject.emtreeBacterial growthen_US
dc.subject.emtreeBacterium cultureen_US
dc.subject.emtreeBurkholderia gladiolien_US
dc.subject.emtreeCitrobacteren_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeCorynebacteriumen_US
dc.subject.emtreeDisease severity assessmenten_US
dc.subject.emtreeEnterococcusen_US
dc.subject.emtreeEscherichia colien_US
dc.subject.emtreeFournier gangreneen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman tissueen_US
dc.subject.emtreeKlebsiella pneumoniaeen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMethicillin-resistant staphylococcus epidermidisen_US
dc.subject.emtreeMorganella morganiien_US
dc.subject.emtreeMortality rateen_US
dc.subject.emtreeNonhumanen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreePseudomonas aeruginosaen_US
dc.subject.emtreeSerratiaen_US
dc.subject.emtreeStaphylococcus aureusen_US
dc.subject.emtreeStreptococcus anginosusen_US
dc.subject.emtreeFournier gangreneen_US
dc.subject.emtreeMicrobial sensitivity testen_US
dc.subject.emtreeMicrobiologyen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeProspective studyen_US
dc.subject.emtreeVery elderlyen_US
dc.subject.emtreeFemaleen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
File Description SizeFormat 
Yılmazlar_vd_2017.pdf198.79 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons